FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposed reforms to the Orange Book patent listing procedures would allow companies to list patents covering polymorphs and some types of manufacturing processes
You may also be interested in...
FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule
FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
FDA's final rule to reform Hatch/Waxman requires an innovator company to test data to establish that a polymorph claimed in a patent is the same as the active ingredient in the NDA
FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
Patent declaration forms must be used for Orange Book submission of patent information under FDA's generic reform final rule